Judging by fridays post market gainer, what's the best investment for monday

**Best shot for Monday’s open: INmune Bio (INMB)⚡**

Friday’s after-hours leader board was dominated by micro-caps, but among them **INMB has the most durable catalyst and the cleanest “continuation” setup for Monday**:

* • +26.6 % post-market jump after announcing new Phase-2 Alzheimer’s data to be presented at Tuesday’s AAIC conference
* • Biotech sympathy tail-wind – Eli Lilly’s donanemab won a positive EU panel vote the same day, putting fresh spotlight on the Alzheimer space
* • Reasonable float (~17 M shares) and short interest (~8 %) = enough fuel for another squeeze yet not so tiny that liquidity evaporates at the open (30-day avg vol ≈ 290 k)

Taken together, INMB offers the highest probability that Friday’s burst will transition into a **“news-into-event” run-up** when Wall Street digests the weekend headlines.

---

### How it stacks up versus the other top after-hours movers

| Rank (after-hrs pct) | Ticker | Catalyst quality | Liquidity & float | Monday risk / reward |
|----------------------|--------|------------------|-------------------|----------------------|
| 111.9 % | **MCVT** | No news – pure momentum; +220 % regular-session already | ~880 k float, <60 k avg vol | Very high fade risk once profit-takers show up |
| 70.9 % | **ANGH** | $23 M convertible note sale | Trades <$1; heavy dilution overhang | Pop often drains at the open; avoid |
| **26.6 %** | **INMB** | Alzheimer data + upcoming conf. | Mid-microcap, decent vol. | Best “event-follow-through” odds |
| 19.1 % | **LOOP** | Insider cluster buys by CEO & directors | ~65 M float, <120 k avg vol | Good story, but insiders may have filled the gap already |
| 16.2 % | **EKSO** | Earnings Monday after close; no surprise leak | Illiquid & down 79 % Y/Y | Likely pre-earnings chop |

---

### Monday game-plan for INMB 📝

1. Mark the **pre-market high** (if > $3.40); treat it as your breakout trigger.
2. **Entry window:** 09:50-10:10 a.m. ET – after the opening volatility dies down.
3. Wait for **1-min VWAP** reclaim *and* volume >1.5× the 20-min average to confirm real demand.
4. Initial stop = last 5-min swing low (typically ≈ 6-8 % below entry).
5. First target = +15 % (matches median day-two extension for similar biotech news), then trail with 9-EMA on the 5-min chart.
6. Flat by 11:30 a.m. if target not hit; Alzheimer conference is Tuesday – you can always re-enter on strength.

---

### Quick word on risk ☂️

• **Micro-cap biotechs swing hard** – size positions so a total loss on the trade would cost <1 % of your portfolio.
• Have a hard stop in the system; slippage is real when liquidity thins.
• This is a **tactical trade**, not a long-term investment thesis.

---

### If you prefer something tamer…

Loop Industries (LOOP) offers a lower-volatility alternative: insider conviction plus ESG tailwinds. Look for a pull-back to $1.20–$1.25 (the 20-EMA on the 30-min) before nibbling.

---

**Bottom-line:** Among Friday’s after-hours gainers, **INMB is the only name with a forthcoming headline that can keep the spotlight on Monday**. Trade the setup, respect the stops, and let the catalyst work for you. Good luck out there! 🍀📈

> *Not investment advice. Do your own due diligence and consult a professional if needed.*